6.0CiteScore
22 daysTime to First Decision

Journal of Personalized Medicine, Volume 9, Issue 3

September 2019 - 13 articles

Cover Story: Pharmacogenetics and biomarkers are becoming normalised as important technologies to improve drug efficacy rates, reduce the incidence of adverse drug reactions, and make informed choices for targeted therapies. However, their wider clinical implementation has been limited by a lack of robust evidence. Suitable evidence is required before a biomarker’s clinical use, and also before its use in a clinical trial. We have undertaken a review of five pharmacogenetic biomarker-guided randomised controlled trials (RCTs) and evaluated the evidence used by these trials to justify biomarker inclusion. Very different levels of evidence were provided by the trials. We used these observations to write recommendations for future justifications of biomarker use in RCTs and encourage regulatory authorities to write clear guidelines. View this paper.

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (13)

Select all

Case Report

3 Citations

7,771 Views

11 Pages

Adaptive, Iterative, Long-Term Personalized Therapy Management in a Case of Stage IV Refractory NSCLC

Anantbhushan Ranade,
Darshana Patil,
Amit Bhatt,
Rucha Dhasare,
Vineet Datta,
Rajan Datar and
Dadasaheb Akolkar

J. Pers. Med.2019, 9(3), 34;https://doi.org/10.3390/jpm9030034

5 July 2019

In this paper we report long-term therapy management based on iterative de novo molecular and cellular analysis in a case of metastatic non-small cell lung cancer (NSCLC), with prior history of treated colorectal cancer. In the described case tempora...

Full Article

Review

31 Citations

9,474 Views

13 Pages

Barriers and Facilitators to Genetic Testing for Familial Hypercholesterolemia in the United States: A Review

Rachele M. Hendricks-Sturrup,
Kathleen M. Mazor,
Amy C. Sturm and
Christine Y. Lu

J. Pers. Med.2019, 9(3), 32;https://doi.org/10.3390/jpm9030032

1 July 2019

Familial Hypercholesterolemia (FH) is an underdiagnosed condition in the United States (US) and globally, affecting an estimated 1/250 individuals. It is a genetic risk factor for premature cardiovascular disease and is responsible for an estimated 6...

Full Article

Article

42 Citations

10,304 Views

12 Pages

Access to Genetic Counselors in the Southern United States

Catalina Villegas and
Susanne B. Haga

J. Pers. Med.2019, 9(3), 33;https://doi.org/10.3390/jpm9030033

1 July 2019

The expansion of genetic and genomic testing across medical specialties and the changing workforce demographics of certified genetic counselors (CGCs) have led to concerns of a workforce shortage. We assessed the number of genetic counselors working...

Full Article

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

J. Pers. Med. - ISSN 2075-4426

Imprint

Download Flyer